Sargramostim
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
1
Recruiting
1
Completed
1
Sites
3
Countries
1
Endpoints
28
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 28 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 14 of 28 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
3
3
3
2
1
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT02667496Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease | Sargramostim Alzheimer’s disease, MCI / preclinical Alzheimer’s | MCI due to AD | Ph 2 | Withdrawn | 1 | Mar 2017 | - | |
| NCT01409915Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease | Sargramostim Alzheimer’s disease | mild-to-moderate AD | Ph 2 | Completed | 1 | Dec 2019 | - | results |
| SESADPhase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease | Sargramostim Alzheimer’s disease | Alzheimer's disease | Ph 2 | Recruiting | 1 | Nov 2026 | 1 |
Showing 1-3 of 3 trials